Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Association of HLA Diversity With All-Cause Mortality in PLCO

Principal Investigator
Name
Zhiwei Liu
Degrees
Ph.D.
Institution
National Cancer Institute
Position Title
Tenure-Track Investigator
Email
About this CDAS Project
Study
PLCO (Learn more about this study)
Project ID
PLCO-1227
Initial CDAS Request Approval
May 30, 2023
Title
Association of HLA Diversity With All-Cause Mortality in PLCO
Summary
We hypothesize that greater diversity in HLA loci could protect against infections and de novo mutations (heterozygosity advantage hypothesis) by resulting in a higher probability of a robust cytotoxic T lymphocyte response to pathogens and tumor neoantigens. Therefore, individuals with lower diversity in HLA loci could be more likely to have higher all-cause mortality compared to those with greater diversity in HLA loci. However, to our knowledge, the association between HLA diversity and all-cause mortality remains unclear. To test our hypothesis, we propose to utilize GWAS data from individuals of European ancestry to study the association of the similarity of HLA alleles (including zygosity and evolutionary divergence) with all-cause mortality.
Aims

We aim to examine the association of the similarity of HLA alleles (including zygosity and evolutionary divergence) with all-cause mortality.

Collaborators

Ruth Pfeiffer, Division of Cancer Epidemiology and Genetics, National Cancer Institute